Dopamine-1 receptor agonist: Renal effects and its potential role in the management of radiocontrast-induced nephropathy

Journal of Clinical Pharmacology

Volumn 44, Issue 12, 2004, Pages 1342-1351

  Asif, Arif ^a   Epstein, David L ^a   Epstein, Murray ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine 1 receptor agonist; Fenoldopam; Radiocontrast induced nephropathy

Indexed keywords

CONTRAST MEDIUM; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FENOLDOPAM; PLACEBO;

ACUTE KIDNEY FAILURE; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DIURESIS; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION; HEALTH CARE COST; HUMAN; HYPOTENSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PERCUTANEOUS CORONARY INTERVENTION; PROPHYLAXIS; RADIOCONTRAST INDUCED NEPHROPATHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SMOOTH MUSCLE RELAXATION; SODIUM EXCRETION; VASCULAR SMOOTH MUSCLE;

CONTRAST MEDIA; FENOLDOPAM; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY FAILURE, ACUTE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D1;

EID: 8744298393     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004269842     Document Type: Review

References (68)

1. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2000;349:1333-1340.
2. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med. 2003;4(suppl 5):S3-S9.
3. Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv. 2001;52:409-416.
4. Asif A, Epstein M. Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 2004;44:12-24.
5. Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol. 1999;34:685-691.
6. Asif A, Preston RA, Roth D. Radiocontrast-induced nephropathy. Am J Ther. 2003;10;137-147.
7. Mathur VS. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. Rev Cardiovasc Med 2001;2(suppl 1):S4-S8.
8. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis. 1998;31;743-755.
9. Carey RM, Siragy HM, Ragsdale NV, et al. Dopamine-1 and dopamine-2 mechanisms in the control of renal function. Am J Hypertens. 1990;3:59S-63S.
10. Hughes JM, Ragsdale NV, Felder RA, Chevalier RL, King B, Carey RM. Diuresis and natriuresis during continuous dopamine-1 receptor stimulation. Hypertension. 1988;11:169-174.
11. Nichols AJ, Ruffolo RR Jr, Brooks DP. The pharmacology of fenoldopam. Am J Hypertens. 1990;3:116S-119S.
12. Beart PM. Dopamine receptors: classification, properties and drug development. Clin Exp Pharmacol Physiol. 1989;16:511-515.
13. Bakris GL, Lass NA, Clock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors. Kidney Int. 1999;56:206-210.
14. Hunter DW, Chamsuddin A, Bjarnason H, Kowalik K. Preventing contrast-induced nephropathy with fenoldopam. Tech Vasc Interv Radiol. 2001;4:53-56.
15. Madyoon H, Croushore L, Weaver D, Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv. 2001;53:341-345.
16. Kini AA, Mitre CA, Kamran M, et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol. 2002;89:999-1002.
17. Kini AA, Sharma SK. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med. 2001;2(suppl 1):S19-S25.
18. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J. 2002;143:894-903.
19. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290:2284-2291.
20. Szerlip HM. Renal-dose dopamine: fact and fiction. Ann Intern Med. 1991;115:153-154.
21. Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int. 1996;50:4-14.
22. Boppana VK, Dolce KM, Cyronak MJ, Ziemniak JA. Simplified procedures for the determination of fenoldopam and its metabolites in human plasma by high-performance liquid chromatography with electrochemical detection: comparison of manual and robotic sample preparation methods. J Chromatogr. 1989;487:385-399.
23. Takenaka T, Forster H, Epstein M. Characterization of the renal microvascular actions of a new dopaminergic (DA1) agonist, YM435. J Pharmacol Exp Ther. 1993;264:1154-1159.
24. Allison NL, Dubb JW, Ziemniak JA, Alexander F, Stote RM. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther. 1987;41:282-288.
25. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med. 1999; 27:1832-1837.
26. Harvey JN, Worth DP, Brown J, Lee MR. The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. Br J Clin Pharmacol. 1985;19:21-27.
27. Reisin E, Huth MM, Nguyen BP, Weed SG, Gonzalez FM. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension. 1990;15:I59-I62.
28. Carey RM, Stote RM, Dubb JW, Townsend LH, Rose CE Jr, Kaiser DL. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. J Clin Invest. 1984;74: 2198-2207.
29. Shusterman NH, Elliott WJ, White WB. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med. 1993;95:161-168.
30. Elliott WJ, Weber RR, Nelson KS, et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation. 1990;81:970-977.
31. Mathur VS. The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. Rev Cardiovasc Med. 2003;4(suppl 1):S35-S40.
32. Sladen RN. Effect of anesthesia and surgery on renal function. Crit Care Clin. 1987;3:373-393.
33. Poinsot O, Romand JA, Favre H, Suter PM. Fenoldopam improves renal hemodynamics impaired by positive end-expiratory pressure. Anesthesiology. 1993;79:680-684.
34. Weisberg LS, Kurnick PB, Kurnick BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994;45:259-265.
35. Aschermann M, Vojacek J, Humhal J, Krupicka P, Holm V, Tesar D. Early results and complications of percutaneous transluminal coronary angioplasty [in Czech]. Cor Vasa. 1993;35:80-83.
36. Muroya T, Ohe H, Sakai H, et al. A case in which stent insertion is considered to have triggered contrast medium-induced coronary vasospasm. Jpn Circ J. 1999;63:315-318.
37. Cohen DJ, Becker ER, Culler SD, et al. Impact of patient characteristics, complications, and facility volume on the costs and time of cardiac catheterization and coronary angioplasty in 70 catheterization laboratories. Am J Cardiol. 2000;86:595-601.
38. Jain D, Schafer U, Dendorfer A, et al. Neurohumoral activation in percutaneous coronary interventions: apropos often vasoactive substances during and immediately following coronary Rotastenting. Indian Heart J. 2001;53:301-307.
39. Rothbaum DA, Hodes ZI, Linnemeier TJ, Landin RJ, Ball MW. Percutaneous transluminal coronary angioplasty for acute myocardial infarction. Cardiol Clin. 1989;7:837-851.
40. Mager A, Strasberg B, Rechavia E, et al. Clinical significance and predisposing factors to symptomatic bradycardia and hypotension after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1994;74:1085-1088.
41. Whisenant BK, Baim DS, Kuntz RE, Garcia LA, Ramee SR, Carrozza JP. Rheolytic thrombectomy with the Possis AngioJet: technical considerations and initial clinical experience. J Invasive Cardiol. 1999;11:421-426.
42. Lembo NJ, King SB III, Roubin GS, Black AJ, Douglas JS Jr. Effects of nonionic versus ionic contrast media on complications of percutaneous transluminal coronary angioplasty. Am J Cardiol. 1991;67: 1046-1050.
43. Satoh A, Matsuda Y, Sakai H, et al. Coronary artery spasm during cardiac angiography. Clin Cardiol. 1990;13:55-58.
44. Brogan WC III, Hillis LD, Lange RA. Contrast agents for cardiac catheterization: conceptions and misconceptions. Am Heart J. 1991; 22:1129-1135.
45. Arrowood JA, Mohanty PK, Hodgson JM, Dibner-Dunlap ME, Thames MD. Ventricular sensory endings mediate reflex bradycardia during coronary arteriography in humans. Circulation. 1989;80: 1293-1300.
46. Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. Am J Roentgenol. 1991;157:1153-1161.
47. Saeed M, Li HT, Wendland MF, Knollmann F, Higgins CB. Comparison of cardiovascular response to ionic and nonionic magnetic resonance susceptibility contrast agents. Invest Radiol. 1994;29:319-329.
48. Nakamura H, Kurata M, Haruta K, Takeda K. Effects of ionic and nonionic contrast media on cardiohemodynamics and quality of radiographic image during canine angiography. J Vet Med Sci. 1994; 56:91-96.
49. Holm F, Aschermann M, Hornig A, Simek S, Linhart A, Humhal J. Complications in administration of contrast media in the catheterization laboratory: a 5-year retrospective study [in Czech]. Vnitr Lek. 2001;47:444-449.
50. Physician's Desk Reference. 56th ed. Montvale, NJ: Medical Economics Company, 2002:2617-2619, 2658-2659, 3026-3033.
51. Zahedi A, Floras JS, Burns RJ. Absence of heart rate increase during inferoposterior left ventricular hypoperfusion caused by dipyridamole infusion. Can J Cardiol. 1999;15:1345-1349.
52. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int. 2000;57:1675-1680.
53. Cox CD, Tsikouris JP. Preventing contrast nephropathy: what is the best strategy? A review of the literature. J Clin Pharmacol. 2004; 44:327-337.
54. Hoffmann U, Banas B, Fischereder M, Kramer BK. N-Acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points. Kidney Blood Press Res. 2004;27:161-166.
55. Thomsen HS. Contrast-medium-induced nephrotoxicity: are all answers in for acetylcysteine? Eur Radiol. 2001;11:2351-2353.
56. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202-2207.
57. Tepel M, Van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-184.
58. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (The APART Trial). Am J Cardiol. 2002;89:356-358.
59. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002; 40:298-303.
60. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40:1383-1388.
61. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289:553-558.
62. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41:2114-2118.
63. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598-603.
64. Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. Eur Heart J. 2004; 25:212-218.
65. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004;25:206-211.
66. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162:329-336.
67. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328-2334.
68. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators: nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-499.